TL1A

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
TL1A (Human)

GtoPdb Ligand ID: 5071

Synonyms: Tumor necrosis factor ligand superfamily member 15, membrane form

Compound class: Endogenous peptide in human, mouse or rat

Comment: TL1A occurs as both membrane‐bound and soluble forms. It principally functions as a negative modulator of epithelial cell proliferation. Inhibiting the TL1A/death receptor 3 (TNFRSF25) pathway has been proposed as mechanism to treat inflammatory bowel disease [1]. In addition, TL1A has been associated with tumourigenesis and progression of some gastrointestinal malignancies [3,5,7], making it a target of interest for the development of novel anti-cancer drugs.

Species: Human

Immunopharmacology Comments
TNF-like ligand 1A (TL1A; TNFSF15) is a TNF family cytokine that is expressed by endotheial cells. It is not expressed by T or B cells. Acting as a ligand for both the death receptor 3 (TNFRSF25) and decoy receptor 3 (TNFRSF6B) it is able activate the NF-κB and MAPK signalling pathways, and it induces fibrogenesis. Overexpression and naturally ocurring polymorphisms in the TNFSF15 gene strongly associate with inflammatory bowel disease [4,6]. TL1A is the target of Pfizer's Phase 2 ulcerative colitis biologic PF-06480605 (NCT01989143 [1] and NCT02840721 [2]).

Immunopharmacology Comments

TNF-like ligand 1A (TL1A; TNFSF15) is a TNF family cytokine that is expressed by endotheial cells. It is not expressed by T or B cells. Acting as a ligand for both the death receptor 3 (TNFRSF25) and decoy receptor 3 (TNFRSF6B) it is able activate the NF-κB and MAPK signalling pathways, and it induces fibrogenesis.
Overexpression and naturally ocurring polymorphisms in the TNFSF15 gene strongly associate with inflammatory bowel disease [4,6].

TL1A is the target of Pfizer's Phase 2 ulcerative colitis biologic PF-06480605 (NCT01989143 [1] and NCT02840721 [2]).